Xu Kai-Yu, Gu Jin
Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Surgery, Peking University School of Oncology, Beijing Cancer Hospital and Institute, Beijing 100142, China.
Zhonghua Wei Chang Wai Ke Za Zhi. 2009 May;12(3):285-9.
To investigate the expression of TROP2 in the left-sided and right-sided colon cancer and its clinical significance.
A total of eighty patients, who received radical resection of colon cancer between June 2001 and April 2005 and were staged as II( and III(, were identified, including forty with left-sided colon cancer(LSCC) and forty with right-sided colon cancer (RSCC). The expression of TROP2 was detected by real-time quantitative RT-PCR in paired cancer and normal tissue. Subsequently, the relationship between TROP2 expression and clinicopathological variables as well as the effect on the patients' prognosis were analyzed.
The expression of TROP2 mRNA in the cancer tissue was significantly higher than that in normal tissue(P<0.01, paired Wilcoxon test). However, its expression in LSCC was markedly higher than that in RSCC with significant difference (P=0.009, Mann-Whitney U test). The patients with TROP2 high expression were found more frequently in LSCC than in RSCC(67.5% vs 32.5%, P=0.002, chi(2) test). Cancer-related mortality of the patients with TROP2 high expression was four times as high as low expression(40% vs 10%, P=0.002, chi(2) test). From the stratified survival analysis through Kaplan-Meier curve, the TROP2 high expression group had a significantly poorer median survival time than the low expression group for the patients with LSCC(45.9:63.1 months, P=0.032, log-rank test). By contrast, for the patients with RSCC, TROP2 expression had no marked effect on the survival time(P=0.235, log-rank test). In multivariable analysis, for the cohort of the present study, serosal invasion and lymphatic/vascular invasion were the independent prognostic factors of RSCC. Serosal invasion, lymph node metastasis and lymphatic/vascular invasion were the independent prognostic factors of LSCC. TROP2 high expression showed marginal significance(RR:6.244, 95% CI:0.755-51.636, P=0.089).
(1)TROP2 is a differentially expressed gene between RSCC and LSCC. (2)TROP2 high expression is closely related to the factors indicating poor prognosis. (3)TROP2 has distinct clinical significance to the patients with different tumor sites. TROP2 high expression is potentially an independent prognostic factor of LSCC. (4)LSCC and RSCC seem to be two distinct diseases with significant molecular heterogeneity.
探讨TROP2在左右侧结肠癌中的表达及其临床意义。
选取2001年6月至2005年4月期间接受结肠癌根治性切除术且分期为II期和III期的80例患者，其中左侧结肠癌（LSCC）40例，右侧结肠癌（RSCC）40例。采用实时定量RT-PCR检测配对的癌组织和正常组织中TROP2的表达。随后，分析TROP2表达与临床病理变量之间的关系以及对患者预后的影响。
癌组织中TROP2 mRNA的表达显著高于正常组织（P<0.01，配对Wilcoxon检验）。然而，其在LSCC中的表达明显高于RSCC，差异有统计学意义（P=0.009，Mann-Whitney U检验）。TROP2高表达的患者在LSCC中比在RSCC中更常见（67.5%对32.5%，P=0.002，卡方检验）。TROP2高表达患者的癌症相关死亡率是低表达患者的4倍（40%对10%，P=0.002，卡方检验）。通过Kaplan-Meier曲线进行分层生存分析，对于LSCC患者，TROP2高表达组的中位生存时间明显短于低表达组（45.9:63.1个月，P=0.032，对数秩检验）。相比之下，对于RSCC患者，TROP2表达对生存时间无明显影响（P=0.235，对数秩检验）。在多变量分析中，对于本研究队列，浆膜侵犯和淋巴/血管侵犯是RSCC的独立预后因素。浆膜侵犯、淋巴结转移和淋巴/血管侵犯是LSCC的独立预后因素。TROP2高表达显示出边缘显著性（RR:6.244，95%CI:0.755-51.636，P=0.089）。
（1）TROP2是RSCC和LSCC之间差异表达的基因。（2）TROP2高表达与提示预后不良的因素密切相关。（3）TROP2对不同肿瘤部位的患者具有不同的临床意义。TROP2高表达可能是LSCC的独立预后因素。（4）LSCC和RSCC似乎是两种具有显著分子异质性的不同疾病。
Zotero 插件